The Walloon government has labeled NeuroPath’s R&I project NeuroInsights joins a portfolio of 49 R&I projects

10 million people worldwide are suffering from Parkinson’s disease (PD) and this number is likely to double over the next 10 to 15 years.  There is no cure yet.

PD is the fastest growing neurodegenerative disease.  PD is complex as over 60 symptoms can occur. A personalized care path is therefore critical for the quality of life of the patient.

The problem is that the standard care path for a person diagnosed with Parkinson’s is only 2 visits per year at the neurologist, compounded by a growing shortage of trained PD neurologists.

The lack of touchpoints between the patient, the neurologist and other care providers can create delays in adapting the personal care path.  This affects the patient’s quality of life and increases health costs unnecessarily, thus placing a tremendous burden on patients, their families and the healthcare system.

NeuroInsights provides a Digital Health Platform to connect the daily living of the patient with the interdisciplinary team of care providers and clinicians.

Our platform gathers data from patient-centric, non-intrusive technologies in motion capturing, patient reported outcomes, voice analysis and wearables. We then create insights to detect specific events, disease progression and treatment efficacy that allows the team to adapt the care path accordingly for an improved quality of life at a lower burden.

This project is led by NeuroPath in collaboration with Multitel, ULiège / CHU, Artevelde Hogeschool and Eonix.

The 36-month project with a budget of € 3.4 million is expected to start in the second half of 2020 and will be monitored by the BioWin and MecaTech clusters.